US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Boston Scientific
(NY:
BSX
)
42.60
-0.63 (-1.46%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Boston Scientific
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
These S&P500 stocks are gapping in today's session
↗
March 30, 2026
Via
Chartmill
These S&P500 stocks that are showing activity before the opening bell on Monday.
↗
March 30, 2026
Via
Chartmill
Boston Scientific Corp (NYSE:BSX) Presents a Compelling Mix of Strong Fundamentals and Technical Breakout Potential
↗
March 28, 2026
Via
Chartmill
The $1 Trillion Resurrection: Global M&A Hits Historic Milestone in Q1 2026 as Jefferies Eyes 'Strategic Renaissance'
March 27, 2026
The global mergers and acquisitions (M&A) market has roared back to life in the first quarter of 2026, shattering expectations and signaling a definitive end to the dealmaking drought of previous...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Initial Public Offering
Boston Scientific Corp (NYSE:BSX): A GARP Stock with Strong Growth and Reasonable Valuation
↗
March 12, 2026
Via
Chartmill
BOSTON SCIENTIFIC CORPORATION (BSX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming Deadline
March 26, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
March 25, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX
March 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Why Boston Scientific's Big Dip Could Be a Bigger Opportunity
↗
March 24, 2026
Via
MarketBeat
BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Concealing Unsustainable U.S. Electrophysiology Segment Growth Rate: Levi & Korsinsky
March 24, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Boston Scientific Corporation (BSX)
March 24, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips
March 19, 2026
As the first quarter of 2026 draws to a close, the U.S. financial landscape has been reshaped by a staggering surge in corporate consolidation. Total deal value for the quarter reached a historic...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Workforce
BOSTON SCIENTIFIC CORPORATION (BSX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming Deadline
March 19, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
BSX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
March 18, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms
March 18, 2026
In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from...
Via
MarketMinute
Topics
Artificial Intelligence
Intellectual Property
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX
March 17, 2026
From
Pomerantz LLP
Via
GlobeNewswire
BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims Executives Misrepresented U.S. Electrophysiology Volumes: Levi & Korsinsky
March 17, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Boston Scientific Corporation (BSX)
March 17, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Movers and shakers in today's after-hours session for S&P500 stocks?
↗
March 16, 2026
Via
Chartmill
Which stocks are moving after the closing bell on Monday?
↗
March 16, 2026
Via
Chartmill
INVESTOR NOTICE: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
March 16, 2026
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment
↗
March 15, 2026
EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships.
Via
The Motley Fool
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement
↗
March 15, 2026
This medical technology firm delivers advanced noninvasive monitoring and automation solutions to healthcare providers worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
↗
March 15, 2026
This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.
Via
The Motley Fool
This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share
↗
March 15, 2026
RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials.
Via
The Motley Fool
Deadline Alert: Boston Scientific Corporation (BSX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
March 12, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
BOSTON SCIENTIFIC CORPORATION (BSX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Boston Scientific Corporation Investors of Upcoming Deadline
March 12, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Medical Technology Alert: BSX, TFX, ARAY, CSDX, NDRA Emerging Across Cancer Treatment and GLP-1 Healthcare Ecosystems
March 11, 2026
Via
AB Newswire
This $9 Million Institutional Buy Targeted a Semiconductor Stock Down 19% Over the Past Year
↗
March 11, 2026
Skyworks Solutions delivers semiconductor products for wireless and analog applications across diverse global markets.
Via
The Motley Fool
Topics
Regulatory Compliance
OLED Stock Down 35% This Past Year, but One Fund Invested $9 Million More Anyway
↗
March 11, 2026
Universal Display licenses OLED tech and supplies materials to major players in the global display and lighting markets.
Via
The Motley Fool
Topics
Intellectual Property
Regulatory Compliance
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
